Autres langues Willow Biosciences Inc. Canadian Securities Exchange

Actions

WLLW

CA97111B4047

Temps Différé Canadian Securities Exchange Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^CAD	-.--%		-.--%	-.--%

13/05	Willow Biosciences Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
01/04	Willow Biosciences réduit sa perte pour 2023 en glissement annuel	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Willow Biosciences Brief: Reiterating its Expectations of at least doubling its full year 2024 revenues, As Reports Q1 Results	13/05
Willow Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Willow Biosciences Narrows 2023 Loss YOY	01/04
Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF	29/03
Willow Biosciences Announces Second Strategic Investment From Kalsec	01/03
Willow Biosciences Secures Strategic Investment From Kalsec to Develop Natural Food Ingredient	21/02
Willow Biosciences Inc. announced that it expects to receive funding from Kalsec Inc.	20/02
Willow Biosciences Enters Partnership With Global Ingredient Manufacturer	31/01
Willow Biosciences Inc. Announces Collaboration with Global Active Pharmaceutical Ingredient Manufacturer to Develop A More Sustainable, Cost-Effective Manufacturing Process for A Large Volume Global Market	31/01
WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT	31/01
Willow Biosciences Announces Collaboration with Active Pharmaceutical Ingredient Manufacturer to Manufacture More Sustainable, Cost-Effective Manufacturing Route for Their Largest Product Sold Globally	31/01
Willow Biosciences Announces Collaboration With Enterin	16/01
Willow Biosciences Inc. Announces Collaboration with Enterin, Inc. to Develop Sustainable Interimates and Active Pharmaceutical Ingredients	16/01
WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS	16/01
Willow Biosciences Highlights Growth Plans for 2024, Provides 2023 Highlights	10/01
Willow Biosciences prevé que 2024 será un gran año -- Market Talk	10/01
Willow Biosciences Brief: Says Plans For "Significant" Growth In 2024	10/01
Willow Bioscience plans to advance development program with Nasdaq-listed company	11/12
Toronto Stocks Flat; Laurentian Bank of Canada Declines on Lower 4Q Profit, Revenue	07/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Willow Biosciences Inc. Canadian Securities Exchange

Actions

WLLW

CA97111B4047

Autres langues

Filtres